SCHEMBL9984378

SCHEMBL9984378

CC(C)(C)OC(=O)C1CCN(c2ccc(Nc3nc(Cl)ccc3[N+](=O)[O-])cc2F)C(N)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.37
MAPT P10636 7/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
JAK2 O60674 2/20 0.35
JAK1 P23458 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
FGFR4 P22455 1/20 0.35
MALT1 Q9UDY8 1/20 0.34
GPR119 Q8TDV5 4/20 0.33
RET P07949 1/20 0.33
ROS1 P08922 1/20 0.33
FLT3 P36888 1/20 0.33
EML4 Q9HC35 1/20 0.33
ALK Q9UM73 1/20 0.33
GPR174 Q9BXC1 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9984369 0.81 FGFR4 (0.35) SYKMAPTL3MBTL1FGFR4GPR119
SCHEMBL9983804 0.80 SYK (0.41) SYKMAPTL3MBTL1FGFR4RET
SCHEMBL9985521 0.79 MAPT (0.57) SYKMAPTL3MBTL1CYP1A2CYP3A4
SCHEMBL29608260 0.79 MAPT (0.46) MAPTL3MBTL1HTT
SCHEMBL28773871 0.79 MAPT (0.46) MAPTL3MBTL1HTT
SCHEMBL9987980 0.78 TDP1 (0.49) MAPTL3MBTL1JAK2CYP1A2CYP3A4
SCHEMBL9985257 0.75 MAPT (0.48) MAPTL3MBTL1FGFR4RETROS1
SCHEMBL9985154 0.75 MAPT (0.45) MAPTCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL9984049 0.73 MAPT (0.44) SYKMAPTL3MBTL1JAK2JAK1
SCHEMBL9984259 0.73 ALDH1A1 (0.50) MAPTL3MBTL1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306606-A1 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME DONG WHA PHARM. CO., LTD. (KR) 2011-12-15 US disclosed
EP-2394993-A2 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Dong Wha Pharm. Co., Ltd. (KR) 2011-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306606-A1 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME NOS3, PTMS, NOS2 SYK 1244/4885MAPT 4055/4885L3MBTL1 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.